Follow-up Report on the Diagnosis of Diabetes Mellitus

Diabetes Care

Volumn 26, Issue 11, 2003, Pages 3160-3167

  Genuth, Saul ^a   Alberti, K G M M ^a   Bennett, Peter ^a   Buse, John ^a   DeFronzo, Ralph ^a   Kahn, Richard ^a   Kitzmiller, John ^a   Knowler, William ^a   Lebovitz, Harold ^a   Lernmark, Ake ^a   Nathan, David ^a   Palmer, Jerry ^a   Rizza, Robbert ^a   Saudek, Christopher ^a   Shaw, Jonathan ^a   Steffes, Michael ^a   Stern, Michael ^a   Tuomilehto, Jaakko ^a   Zimmet, Paul ^a  

^a The Expert Committee on the Diagnosis and Classification of Diabetes ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC DIET; DIABETIC RETINOPATHY; DIAGNOSTIC TEST; FASTING BLOOD GLUCOSE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; ORAL GLUCOSE TOLERANCE TEST; REVIEW;

BLOOD GLUCOSE; DIABETES MELLITUS; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS;

EID: 0242300698     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.11.3160     Document Type: Review

References (80)

1. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979
2. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)
3. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183-1197, 1997
4. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999
5. DECODE Study Group on Behalf of the European Diabetes Epidemiology Study Group: Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 317:371-375, 1998
6. Larsson H, Berglund G, Lindgarde F, Ahren B: Comparison of ADA and WHO criteria for diagnosis and glucose intolerance (Letter). Diabetologia 41:1124-1125, 1998
7. Davies MJ, Raymond NT, Day JL, Hales CN, Burden AC: Impaired glucose tolerance and the fasting hyperglycaemia have different characteristics. Diabet Med 17:433-440, 2000
8. Rathmann W, Giant G, Mielck A: Cardiovascular risk factors in newly diagnosed abnormal glucose tolerance: comparison of 1997 ADA and 1985 WHO criteria (Letter). Diabetologia 42:1268-1269, 1999
9. Hanefield M, Temelkova-Kurktschiev T, Schaper F, Henkel E, Siegert G, Koehler C: Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med 16:212-218, 1999
10. The DECODE Study Group, the European Diabetes Epidemiology Group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2 2-hour diagnostic criteria. Arch Intern Med 161:397-404, 2001
11. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascuar and noncardiovascular diseases? Diabetes Care 26:688-696, 2003
12. Little RR: Glycated hemoglobin standardization: National Glycohemoglobin Standardization Program (NGSP) Perspective (Review). Clin Chem. Lab Med. In Press
13. Peters AL, Davidson MB, Schriger DL, Hasselblad V: A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels: Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. JAMA 276:1246-1252, 1996
14. 1c) in screening for undiagnosed diabetes in the U. S. population. Diabetes Care 23:187-191, 2000
15. 1c to improve efficacy of the American diabetes association fasting plasma glucose criterion in screening for new type 2 diabetes in American Indians. Diabetes Care 25:1365-1370, 2002
16. Barr RG, Nathan DM, Meigs JB, Singer DE: Tests of glycemia For the diagnosis of type 2 diabetes mellitus. Ann Intern Med 137:263-272, 2002
17. 1c or fructosamine predicts the likelihood of having diabetes in high-risk subjects Diabetes Care 21:1221-1225, 1998
18. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämätäinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
19. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
20. Wenying Y, Lixiang L, Jimevu Q, Zhiqing Y, Haicheng P, Guofeng H, et al: The preventative effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3 year multicenter prospetive study. Clin J Endocrinol Metab 17:131-135, 2001
21. Chiasson JL, Josse Rg, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359:2072-2077, 2002
22. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796-2803, 2002
23. Rusforth NB, Bennett PH, Miller M: Fasting and two-hour post-blood glucose levels for the diagnosis of diabetes: the relationship between glucose levels and complications of diagetes in the Pima Indians. Diabetologia 16:373-379, 1970
24. Zimmet P, Whitehouse S: Bimodality of fasting and two-hour glucose tolerance distributed in a Micronesian population. Diabetes 27:793-800, 1970
25. Smith NL, Barzilay JI, Shaffer D, Savage PJ, Heckbert SR, Kuller LH, Kronmal RA, Resnick HE, Psaty BM: Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: the Cardiovascular Health Study. Arch Intern Med 162:209-216, 2002
26. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, Knowler WC: The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23:1108-1112, 2000
27. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS: Comparison of diabetes diagnostic categories in the U. S. population according to 1997 American Diabetes Association and 1980-1985 World Health Organization diagnostic criteria. Diabetes Care 20:1859-1862, 1997
28. Shaw JE, Zimmet PZ, Hodge AM, de Courten M, Dowse GK, Chitson P, Tuomilehto J, Alberti KGMM: Impaired fasting glucose: how low should it go? Diabetes Care 23:34-39, 2000
29. Burtis CA, Ashwood ER: Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia, W.B. Saunders, 1999, p. 782
30. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 48:436-472, 2002
31. Unwin N, Shaw J, Zimmer P, Alberti KGMM: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19:708-723, 2002
32. Bortheiry AL, Malerbi DA, Franco LJ: The ROC curve in the evaluation of fasting capillary blood glucose as a screening test for diabetes and IGT. Diabetes Care 17:1269-1272, 2002
33. Dyson PA, Hammersley MS, Morris RJ, Holman RR, Turner RC: The Fasting Hyperglycaemia Study. II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose. Metabolism 46 (12 Suppl. 1):50-55, 2002
34. Sacks DB: College of American Pathologists Glycohemoglobic Survey 2002. Set GH2-A, CAP2000
35. Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233-240, 1997
36. Balkau B, Bertrais S, Ducimetiere P, Eschwege E: Is there a glycemic threshold for mortality risk? Diabetes Care 22:696-699, 1997
37. Bjomholt JV, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J, Erikssen J, Thaulow E: Fasting blood glucose: an underestimated risk factor for cardiovascular death: results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care 22:45-49, 1999
38. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H: Coronary-heart-disease risk and impaired glucose tolerance: the Whitehall study. Lancet 1:1373-1376, 1980
39. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL: Postchallenge hyperglycemia and mortality in a national sample of U. S. adults. Diabetes Care 24:1397-5402, 2001
40. Eschwege E, Charles MA, Simon D, Thibult N, Balkau B: From policemen to policies: what is the future for 2-h glucose? The Kelly West Lecture, 2000. Diabetes Care 24:1945-1950, 2001
41. de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn Study. Diabetes Care 23:40-44, 2000
42. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 42:926-931, 1999
43. The DECODE Study Group, European Diabetes Epidemiology Group: Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe: glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-621, 1999
44. Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, Furberg CD, Dobs A, Polak JF, Savage PJ: Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 354:622-625, 1999
45. Barrett-Connor E, Ferrara A: Isolated post-challenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men: the Rancho Bernardo Study. Diabetes Care 21:1236-1239, 1998
46. Rodriguez BL, Lau N, Burchfiel CM, Abbott RD, Sharp DS, Yano K, Curb JD: Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care 22:1262-1265, 1999
47. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 22:920-924, 1999
48. Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ: Isolated post-challenge hyperglycaemia confirmed as a risk factor from mortality. Diabetologia 42:1050-1054, 1999
49. Gabir M, Hanson RL, Debelea D, Imperatore G, Rousmain J, Bennett PH, Knowler WC: Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care 23:1113-1118, 2000
50. Balkau B, Forhan A, Eschwege E: Two hour plasma glucose is not unequivocally predictive for early death in men with impaired fasting glucose: more results from the Paris Prospective Study. Diabetologia 45:1224-1230, 2002
51. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW: Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 25:1845-1850, 2002
52. Stern MP, Fatehi P, Williams K, Haffner SM: Predicting future cardiovascular disease: do we need the oral glucose tolerance test? Diabetes Care 25:1851-1856, 2002
53. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP: Excess mortality among individuals with impaired glucose tolerance (IGT) is limited to those who develop diabetes: the San Antonio Heart Study (Abstract). Diabetes 51 (Suppl. 2): A229, 2002
54. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
55. Chiasson J-L, Josse RG, Gormis R, Hanefeld M, Karasik A, Laakso M, the STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486-494, 2003
56. Harris MI, Eastman RC: Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes Metab Res Rev 16:230-236, 2000
57. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 26 (Suppl. 1):S33-S50, 2003
58. Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D: Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. J Clin Invest 74:1238-1246, 1984
59. Ferrannini E, Bjorkman O, Reichard GA Jr, Pilo A, Olsson M, Wahren J, DeFronzo RA: The disposal of an oral glucose load in healthy subjects: a quantitative study. Diabetes 34:580-588, 1985
60. DeFronzo RA: Lilly Lecture 1987: the triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37:667-687, 1988
61. Weyer C, Bogardus C, Pratley RE: Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 48:2197-2203, 1999
62. Reaven GM: Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
63. Haffner SM, Stem MP, Hazuda HP, Mitchell BD, Patterson JK: Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263:2893-2898, 1990
64. Edwards KL, Austin MA, Newman B, Mayer E, Krauss RM, Selby JV: Multivariate analysis of the insulin resistance syndrome in women. Arterioscler Thromb 14:1940-1945, 1994
65. Meigs JB, D'Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE: Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes 46:1594-1600, 1997
66. Gray RS, Fabsitz RR, Cowan LD, Lee ET, Howard BV, Savage Pj: Risk factor clustering in the insulin resistance syndrome: the Strong Heart Study. Am J Epidemiol 148:869-878, 1998
67. Hanson RL, Imperatore G, Bennett PH, Knowler WC: Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 51:3120-3127, 2002
68. Tuomilehto J: Point: a glucose tolerance test is important for clinical practice. Diabetes Care 25:1880-1882, 2002
69. Davidson MB: Counterpoint: the oral glucose tolerance test is superfluous. Diabetes Care 25:1883-1885, 2002
70. Feskens EJ, Bowles CH, Kromhout D: Intra- and interindividual variability of glucose tolerance in an elderly population. J Clin Epidemiol 44:947-953, 1991
71. McDonald GW, Fisker GF, Burnham C: Resproducibility of the oral glucose tolerance test. Diabetes 14:473-480, 1965
72. Olefsky JM, Reaven GM: Insulin and glucose responses to identical oral glucose tolerance tests performed forty-eight hours apart. Diabetes 23:449-453, 1974
73. Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM, Heine RJ: Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 39:298-305, 1996
74. Ko GT, Chan JC, Woo J, Lau E, Yeung VT, Chow CC, Cockram: The reproducibility and usefulness of the oral glucose tolerance test in screening for diabetes and other cardiovascular risk factors. Ann Clin Biochem 35:62-67, 1998
75. Burke JP, Haffner SM, Gaskill SP, Williams KL, Stern MP: Reversion from type 2 diabetes to nondiabetic status: influence of the 1997 American Diabetes Association criteria. Diabetes Care 21:1266-1270, 1998
76. Eschwege E, Charles MA, Simon D, Thibult N, Balkau B: Reproducibility of the diagnosis of diabetes over a 30-month follow-up: the Paris Prospective Study. Diabetes Care 24:1941-1944, 2001
77. Stem MP, Williams K, Haffner SM: Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136:575-581, 2002
78. Ruige JB, de Neeling JN, Kostense PJ, Bouter LM, Heine RJ: Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Diabetes Care 20:491-496, 1997
79. Baan CA, Ruige JB, Stolk RP, Witteman JC, Dekker JM, Heine RJ, Feskens EJ: Performance of a predictive model to identify undiagnosed diabetes in a health care setting. Diabetes Care 22:213-219, 1999
80. Lindstrom J, Tuomilehto J: The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26:725-731, 2003